Literature DB >> 23600136

[Progress in the fragment-based drug discovery].

Jing Ren1, Jian Li, Feng Shi, Xin Wang, Jian-Hua He, Ye-Chun Xu, Nai-Xia Zhang, Bing Xiong, Jing-Kang Shen.   

Abstract

As an extension of the structure-based drug discovery, fragment-based drug discovery is matured increasingly, and plays an important role in drug development. Fragments in a small library, with lower molecular mass and high "ligand efficiency", are detected by SPR, MS, NMR, X-ray crystallography technologies and other biophysical methods. Then they are considered as starting points for chemical optimization with the guidance of structural biology methods to get good "drug-like" lead and candidate compounds. In this article, we reviewed the current progress of fragment-based drug discovery and detailed a number of examples to illustrate the novel strategies.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23600136

Source DB:  PubMed          Journal:  Yao Xue Xue Bao        ISSN: 0513-4870


  1 in total

1.  Discovery of Novel Dihydrolipoamide S-Succinyltransferase Inhibitors Based on Fragment Virtual Screening.

Authors:  Chengqian Wei; Junjie Huang; Yu Wang; Yifang Chen; Xin Luo; Shaobo Wang; Zengxue Wu; Jixiang Chen
Journal:  Int J Mol Sci       Date:  2021-11-30       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.